GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
TrustPilot
阿卜杜拉·B.
3 周前
拉维·S。
2 个月前
阿里·H.
1天前
